GlassScriptPhysician profile
Jeremy Brooks
NPI 1861873879
$6,770.36
in general payments reported to CMS, 2019-2025
23 companies · $758 in 2025
The $758 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $376 · 2020: $840 · 2021: $1,481 · 2022: $3,204 · 2023: $47.69 · 2024: $64.39 · 2025: $758.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $515 · Food and Beverage: $355.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $514.97 |
| Food and Beverage | $355.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,222.40 | 2019-2022 | |
| Edwards Lifesciences Corporation | $1,310.54 | 2020-2022 | |
| Boston Scientific Corporation | $1,146.74 | 2019-2025 | General - Therapies, General - Catheter |
| Abiomed | $392.72 | 2019-2025 | |
| Medtronic Vascular, INC. | $347.76 | 2019-2020 | |
| Medtronic, INC. | $253.48 | 2021-2025 | Ffrangio, Resolute Onyx |
| Astrazeneca Pharmaceuticals LP | $159.98 | 2019-2022 | |
| Teleflex LLC | $144.02 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $133.71 | 2019-2023 | Lifevest |
| Chiesi USA, INC. | $132.02 | 2021 | |
| Cardiovascular Systems INC. | $124.34 | 2021 | |
| W. L. Gore & Associates, INC. | $78.94 | 2022 | |
| Angiodynamics, INC. | $73.20 | 2021 | |
| Janssen Pharmaceuticals, INC | $50.88 | 2019-2021 | |
| Inspire Medical Systems, INC. | $47.22 | 2024 | Inspire |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biosense Webster, INC. | $32.93 | 2022 | |
| Biotronik INC. | $25.13 | 2020 | |
| Cardiva Medical, INC. | $18.14 | 2022 | |
| Irhythm Technologies, INC. | $17.81 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $17.17 | 2024 | Uptravi, Opsumit |
| E.R. Squibb & Sons, L.L.C. | $14.89 | 2023 | Eliquis |
| Novartis Pharmaceuticals Corporation | $14.19 | 2020 | |
| Amgen INC. | $12.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeremy Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.